To study the effectiveness of oral azathioprine alone and in combination with phototherapy and to compare with combination of oral steroid and phototherapy in treatment of vitiligo patients.

Efficacy of oral azathioprine and systemic steroid in treatment of vitiligo : A randomized control trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/08/009554

Enrollment

Registered

2017-08-30

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- vitiligo Health Condition 2: L80- Vitiligo

Interventions

Intervention1: Tab azathioprine 50 mg OD daily: Tab azathioprine 50 od daily in morning Control Intervention1: Tab. Azathioprine 50 mg OD daily: tablet to be taken daily in morning Control Interventio

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient willing to take part in study 2. Age between 18 and 60 years irrespective of gender 3. Vitiligo involving > 5% body surface area 4. All clinical type of vitiligo

Exclusion criteria

Exclusion criteria: 1. Patient not willing to take part in study 2. Pregnancy, lactation 3. History of photosensitivity or photo aggravated dermatoses 4. History of significant systemic diseases, hypertension or diabetes mellitus 5. Patient with anaemia, pancytopenia, thrombocytopenia, blood disorder 6. Immuno-compramised patient and patient on other immunosuppressive drug

Design outcomes

Primary

Measure	Time frame
1.stability of vitiligo 2. repigmentationTimepoint: baseline, 1 month, 3 month, 6 month, 9 month, 12 month	—

Secondary

Measure	Time frame
side effectsTimepoint: baseline, 15 days, 1 month, 2,3,4,5,6,7,8,9,10,11,12 month	—

Countries

India

Contacts

Public ContactDr Sugat Jawade

Jawaharlal Nehru Medical College

vikrantsaoji@hotmail.com9822697892

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026